tiprankstipranks
Advertisement
Advertisement

RXST Stock Latest News

RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
The FlyRxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
6d ago
RXST
TARS
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
PremiumThe Fly
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
14d ago
RXST
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
PremiumThe Fly
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
14d ago
RXST
RxSight price target lowered to $6.50 from $7.50 at Jefferies
PremiumThe Fly
RxSight price target lowered to $6.50 from $7.50 at Jefferies
14d ago
RXST
RxSight price target lowered to $6.50 from $8 at BofA
PremiumThe Fly
RxSight price target lowered to $6.50 from $8 at BofA
14d ago
RXST
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
PremiumRatingsRxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target Reiterated
14d ago
RXST
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
Premium
Company Announcements
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
15d ago
8K
RXST
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
Premium
The Fly
Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs
15d ago
ALC
RXST
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
PremiumThe Fly
Alcon, RxSight announce collaboration to develop adjustable PCIOLs
15d ago
ALC
RXST
RxSight Stockholders Back Leadership at 2026 Annual Meeting
PremiumCompany Announcements
RxSight Stockholders Back Leadership at 2026 Annual Meeting
1M ago
8K
RXST
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
PremiumClass Action
RxSight Securities Lawsuit Advances After Court Denies Dismissal Bid
2M ago
RXST
RxSight Earnings Call Balances Growth With Headwinds
PremiumCompany Announcements
RxSight Earnings Call Balances Growth With Headwinds
2M ago
RXST
RxSight price target lowered to $11 from $13 at Needham
PremiumThe FlyRxSight price target lowered to $11 from $13 at Needham
3M ago
RXST
RxSight reports Q1 adjusted EPS (19c), consensus (15c)
Premium
The Fly
RxSight reports Q1 adjusted EPS (19c), consensus (15c)
3M ago
RXST
RxSight backs FY26 revenue view $120M-$135M, consensus $129.22M
Premium
The Fly
RxSight backs FY26 revenue view $120M-$135M, consensus $129.22M
3M ago
RXST
William Blair med tech analyst holds an analyst/industry conference call
PremiumThe Fly
William Blair med tech analyst holds an analyst/industry conference call
3M ago
ALC
COO
RxSight price target lowered to $9 from $10 at Stifel
PremiumThe Fly
RxSight price target lowered to $9 from $10 at Stifel
4M ago
RXST
RxSight Earnings Call: Strong Core, Cautious Outlook
PremiumCompany Announcements
RxSight Earnings Call: Strong Core, Cautious Outlook
4M ago
RXST
RxSight price target lowered to $10 from $11 at Piper Sandler
PremiumThe Fly
RxSight price target lowered to $10 from $11 at Piper Sandler
5M ago
RXST
RxSight price target raised to $9 from $8 at UBS
PremiumThe FlyRxSight price target raised to $9 from $8 at UBS
5M ago
RXST
RxSight reports Q4 EPS (3c), consensus (20c)
Premium
The Fly
RxSight reports Q4 EPS (3c), consensus (20c)
5M ago
RXST
RxSight sees FY26 revenue $120M-$135M, consensus $135.34M
Premium
The Fly
RxSight sees FY26 revenue $120M-$135M, consensus $135.34M
5M ago
RXST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >